Kinnate Biopharma Inc.

NasdaqGS:KNTE Stock Report

Market Cap: US$125.1m

Kinnate Biopharma Balance Sheet Health

Financial Health criteria checks 6/6

Kinnate Biopharma has a total shareholder equity of $159.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $173.6M and $14.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$154.03m
EquityUS$159.33m
Total liabilitiesUS$14.28m
Total assetsUS$173.61m

Recent financial health updates

Recent updates

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Jun 11
Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Jan 04
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Sep 21

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15
Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24
Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09
We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22
Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03
We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

Financial Position Analysis

Short Term Liabilities: KNTE's short term assets ($158.2M) exceed its short term liabilities ($12.0M).

Long Term Liabilities: KNTE's short term assets ($158.2M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: KNTE is debt free.

Reducing Debt: KNTE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KNTE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KNTE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.1% each year


Discover healthy companies